84 results about "Alpha globulin" patented technology

The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.

A process for modifying the lactoprotein by enzyme method features that the immobilized composite enzyme, the ionically regulatory protein structure and heat treating technique are used as selectively hydrolyze the alpha S-casein and beta-lactoglobulin in lactoprotein, resulting in easy digestion and low sensitization. It can be used for composite milk for baby, old man and patient.

The invention discloses a method for separating and detecting whey proteins, which comprises the following steps: pretreating the whey protein; and completely separating bovine alpha-lactalbumin, bovine beta a-lactoglobulin, and bovine beta b-lactoglobulin in a sample by an ultra-performance liquid chromatography column taking 1.7 mu m ethylidene bridged hybrid (BEH) particles as a filler, and performing section scan by a mass analyzer to quantitate the unmodified bovine lactalbumin and lactoglobulin. In the method, human alpha-lactalbumin is added as internal standard. The method can accurately measure the contents of the three types of unmodified bovine whey proteins in multiple kinds of food, and has simple pretreatment, high sensitivity, quick detection speed and good selectivity.

The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., over-expression of beta-2 microgobulin (B2M), keratin 17 (KRT17), interleukin 8 (IL8), or annexin A2 (ANXA2), and under-expression of cytochrome p450 1B1 (CYP1B1) or laminin gamma-2 (LAMC2) can be indicative of the likelihood a subject has squamous cell carcinoma or a precancerous squamous cell disorder. The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. The expression levels of B2M, CYP1B1, KRT17, IL8, ANXA2, or LAMC2 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.

The invention provides a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a β2-microglobulin molecule that is linked through its carboxyl terminal to a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a polypeptide stretch consisting of the full or partial transmembrane and/or cytoplasmic domains selected from the group consisting of a toll-like receptor (TLR) polypeptide, a CD40 polypeptide, and TLR and CD40 polypeptides fused in tandem, that allows the anchorage of the β2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising an MHC class I epitope, wherein said antigenic peptide is preferably derived from a tumor-associated antigen or from a pathogenic antigen. Antigen presenting cells and DNA and cellular vaccines for treatment of cancer and infectious diseases, are also provided.

The present invention is directed to 5′ regulatory regions of a cotton seed-specific gene, α-globulin. The 5′ regulatory region, or parts thereof, when operably linked to either the coding sequence of a native gene, heterologous gene or a sequence complementary to a native plant gene, direct expression of the coding sequence or complementary sequence in a plant seed. The regulatory regions are useful in expression cassettes and expression vectors for the transformation of plants. Also provided are methods of modulating the levels of a native or heterologous gene such as a fatty acid synthesis or lipid metabolism gene by transforming a plant with the subject expression cassettes and expression vectors.

The invention discloses an aptamer probe for detecting alpha-lactalbumin, beta-lactoglobulin and lactoferrin, and belongs to the technical field of IA (immunoassay) of food analysis. The nucleotide sequence of the aptamer probe for detecting alpha-lactalbumin, beta-lactoglobulin and lactoferrin disclosed by the invention is shown as SEQ ID NO. 1-3. According to a method disclosed by the invention,the contents of the alpha-lactalbumin, the beta-lactoglobulin and the lactoferrin can be simultaneously detected quickly and accurately; the method is high in sensitivity, short in detection time andsimple and easy to operate.

This invention provides an HLA class I-expressing non-human animal that can be prepared efficiently in a simple manner within a short period of time, in which the transgene copy number to be introduced thereinto and the integration site of transgene are regulated, and in which the expression level of the transgene and the site of expression thereof are regulated. The invention also provides a method for preparing such non-human animal. In such HLA class I gene knock-in non-human animal, an artificial chimeric gene encoding an artificial chimeric protein comprising a protein composed of β2 microglobulin, HLA class I α1 and α2 regions, and an MHC class I α3 region of a non-human animal ligated in such order from the N terminus is expressed under the control of a transcription regulatory region of β2 microglobulin gene of the non-human animal.

The present invention relates generally to mutagenesis of target genes that enhances the natural mutagenic capabilities of adaptive immune cells by providing a chimeric construct that exploits the ability of molecules such as AID to stimulate diversification and the ability of a second molecule to restrict nuclear activity of the molecules and/or protect cell viability. The invention provides a method for stimulating diversification in expressed genes, such as antibody genes, using polypeptides whose nuclear activity is restricted to specific phases of the cell cycle. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity, or for developing T cells for immunotherapy. The invention provides an improved means of developing a repertoire of variant immunoglobulins and other polypeptides.

The invention belongs to the field of bacteria/livestock microorganisms, and particularly relates to a bacillus velezensis strain for soybean meal fermentation. The strain is bacillus velezensis DP-2with a preservation number of CGMCC No.17235. The bacillus velezensis strain DP-2 can efficiently secrete neutral protease and alkaline protease, and has a good degradation effect on anti-nutrient substances such as glycinin and beta-conglycinin in soybean meal; and the degradation rate of the glycinin can reach 81%-96%, the degradation rate of the beta-conglycinin can reach 50%-67%, acid-solubleprotein is increased by 5-6 times, the content of nutrient substances in fermented soybean meal can be remarkably increased, the nutrient utilization rate is remarkably increased, and therefore the nutritional value of the soybean meal is improved.

The present disclosure provides a method for treating lupus, Sjogren's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor alpha (IL-3R alpha) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

The invention discloses ferritin-based monofunctionalized magnetic nanometer particle. The ferritin-based monofunctionalized magnetic nanometer particle comprises a monofunctionalized ferritin shell and a magnetic nanometer particle core. The monofunctionalized ferritin shell is an asymmetric globulin with a tetrahedral structure. The asymmetric globulin mainly comprises one mutant Dps subunit and eleven wild Dps subunits. The Dps is a starvation-induced DNA binding protein. The ferritin-based monofunctionalized magnetic nanometer particle is prepared from biomacromolecule-protein as a template material, can be reconstructed easily, can be operated conveniently, is convenient for large-scale acquisition, has only one functional group and has an important meaning for follow-up controllable assembling.

The present application provides an infant milk protein partially hydrolyzed formula for special medical use comprising hydrolyzed whey protein prepared from alkaline protease or trypsin hydrolyzed whey protein. According to the formula food disclosed by the invention, good flavor is maintained through moderate hydrolysis, and meanwhile, the sensitization of beta-lactoglobulin is effectively reduced.

The invention provides an in vitro expansion method of NK cells and a kit for the method. According to the method, the NK cells obtained by carrying out in vitro induction and amplification on mononuclear cells which are separated from umbilical cord blood or peripheral blood are subjected to flow cytometry, which shows that the proportion of CD3<->CD16<+>CD56<+> cells reaches 90 percent or above;in addition, the culture better meets the requirements of clinical preparation; the NK cells show good killing activity in vitro and in vivo. On the other hand, the invention provides application ofan HER-antibody and alpha-mannatide for induced differentiation of the NK cells, as well as rabbit anti-human thymocyle immunoglobulin, 1L-15 and IL-2 for amplifying the NK cells in preparing a kit for obtaining high-purity NK cells in vitro.

The invention provides a cow lysozyme (Lyz) gene mammary gland specific expression plasmid as well as a construction method and application thereof. Specifically, a coding sequence of a Lyz gene is subjected to PCR amplification, the Lyz gene is inserted into a multiple cloning site of a universal expression vector pEGFP-N1 carrying an enhanced green fluorescent protein gene; Ase I+Hind III doubleenzyme digestion is conducted on the universal expression vector pEGFP-N1 so as to remove a CMV promoter, a cow mammary gland specific expression beta-lactoglobulin gene (BLG) promoter sequence is cloned, Ase I and HindIII restriction enzyme cutting sites are replaced, and the cow Lyz gene mammary gland specific expression plasmid is constructed. The recombinant plasmid is adopted to transfect cow mammary epithelial cells, and an obtained cell line can be used for secreting cow lysozyme with biological activity and used for cow mammary tissue immune mechanism research; and the recombinant plasmid can also be applied to research and development of preparations for gene therapy of cow mastitis.

The invention is generally directed to antibody variable domains or antibodies, libraries of antibody variable domains or antibodies, methods of making said antibodies and libraries, and methods of treatment comprising administering the generated antibody variable domains or antibodies. Specifically, the invention is directed to novel primer nucleotide sequences that are used to amplify all rearranged sequences of canine variable heavy (VH) and variable light (VL) immunoglobulin chains that have been used in naturally occurring antibody responses. These novel sequences contain canine framework regions and complementarity determining regions which may be used to canine-ize antibodies. Further, these sequences are useful for the identification and targeting of viral and bacterial pathogens, and tumor-associated antigens.

Processes and methods of purifying or separating Single Domain Antigen Binding (SDAB) molecules that include one or more single binding domains (e.g., one or more nanobody molecules), substantially devoid of a complementary antibody domain and an immunoglobulin constant region, using Protein A-based affinity chromatography, are disclosed.

This invention relates to a novel protein (INSP052), herein identified as an immunoglobulin domain-containing cell surface recognition molecule and to the use of this proteins and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease. The invention also relates to the identification of the extracellular domain of INSP052.

The invention belongs to the field of pharmaceutical preparations, in particular to the preparation and application of a gene carrier system. The gene carrier system is a nanocrystal formed by cationized β-lactoglobulin and paclitaxel, and the particle diameter of the nanocrystal is 140-180nm. In the gene carrier system of the present invention, the nanocrystal can electrostatically combine with the gene to form a complex, and protect the gene from being degraded by RNase, so it is a good gene carrier system that can be used for gene therapy. Compared with the existing gene delivery system, the present invention does not contain highly toxic polymers and solvents that are likely to cause allergic reactions, so the safety is greatly improved. In mouse pharmacodynamic experiments, the present invention shows better therapeutic effect.